Aevi's AEVI-001 misses in Phase II for children with ADHD

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) said AEVI-001 missed the primary endpoint in both Parts A and B of the Phase II ASCEND trial to treat ADHD in patients ages 6-17. The company plans to conduct a full review of the data with its scientific advisers to determine next steps. AEVI-001 is an oral non-stimulant, pan-selective activator of mGluRs.

The double-blind, U.S. trial's primary endpoint evaluated the change from baseline in ADHD Rating Scale (ADHD-RS) total score at week six between twice-daily oral AEVI-001 and placebo in ADHD patients with an mGluR copy number variant (Part A; n=69) and without an mGluR copy number variant (Part B; n=109)...